Biomimetic screening of class-B G protein-coupled receptors. 2011

Christian Devigny, and Francisco Perez-Balderas, and Bastiaan Hoogeland, and Serena Cuboni, and Rudolf Wachtel, and Christoph P Mauch, and Katharine J Webb, and Jan M Deussing, and Felix Hausch
Max-Planck-Institute of Psychiatry, Kraepelinstrasse 2-10, 80804 Munich, Germany.

The 41-amino acid peptide corticotropin releasing factor (CRF) is a major modulator of the mammalian stress response. Upon stressful stimuli, it binds to the corticotropin releasing factor receptor 1 (CRF(1)R), a typical member of the class-B G-protein-coupled receptors (GPCRs) and a prime target in the treatment of mood disorders. To chemically probe the molecular interaction of CRF with the transmembrane domain of its cognate receptor, we developed a high-throughput conjugation approach that mimics the natural activation mechanism of class-B GPCRs. An acetylene-tagged peptide library was synthesized and conjugated to an azide-modified high-affinity carrier peptide derived from the CRF C-terminus using copper-catalyzed dipolar cycloaddition. The resulting conjugates reconstituted potent agonists and were tested in situ for activation of the CRF(1) receptor in a cell-based assay. By use of this approach we (i) defined the minimal sequence motif that is required for full receptor activation, (ii) identified the critical functional groups and structure-activity relationships, (iii) developed an optimized, highly modified peptide probe with high potency (EC(50) = 4 nM) that is specific for the activation domain of the receptor, and (iv) probed the behavioral role of CRF receptors in living mice. The membrane recruitment by a high-affinity carrier enhanced the potency of the tethered peptides by >4 orders of magnitude and thus allowed the testing of very weak initial fragments that otherwise would have been inactive on their own. As no chromatography purification of the test peptides was necessary, a substantial increase in screening throughput was achieved. Importantly, the peptide conjugates can be used to probe the endogenous receptor in its native environment in vivo.

UI MeSH Term Description Entries
D008024 Ligands A molecule that binds to another molecule, used especially to refer to a small molecule that binds specifically to a larger molecule, e.g., an antigen binding to an antibody, a hormone or neurotransmitter binding to a receptor, or a substrate or allosteric effector binding to an enzyme. Ligands are also molecules that donate or accept a pair of electrons to form a coordinate covalent bond with the central metal atom of a coordination complex. (From Dorland, 27th ed) Ligand
D002462 Cell Membrane The lipid- and protein-containing, selectively permeable membrane that surrounds the cytoplasm in prokaryotic and eukaryotic cells. Plasma Membrane,Cytoplasmic Membrane,Cell Membranes,Cytoplasmic Membranes,Membrane, Cell,Membrane, Cytoplasmic,Membrane, Plasma,Membranes, Cell,Membranes, Cytoplasmic,Membranes, Plasma,Plasma Membranes
D003346 Corticotropin-Releasing Hormone A peptide of about 41 amino acids that stimulates the release of ADRENOCORTICOTROPIC HORMONE. CRH is synthesized by neurons in the PARAVENTRICULAR NUCLEUS of the HYPOTHALAMUS. After being released into the pituitary portal circulation, CRH stimulates the release of ACTH from the PITUITARY GLAND. CRH can also be synthesized in other tissues, such as PLACENTA; ADRENAL MEDULLA; and TESTIS. ACTH-Releasing Hormone,CRF-41,Corticotropin-Releasing Factor,Corticotropin-Releasing Hormone-41,ACTH-Releasing Factor,CRF (ACTH),Corticoliberin,Corticotropin-Releasing Factor-41,ACTH Releasing Factor,ACTH Releasing Hormone,Corticotropin Releasing Factor,Corticotropin Releasing Factor 41,Corticotropin Releasing Hormone,Corticotropin Releasing Hormone 41
D004353 Drug Evaluation, Preclinical Preclinical testing of drugs in experimental animals or in vitro for their biological and toxic effects and potential clinical applications. Drug Screening,Evaluation Studies, Drug, Pre-Clinical,Drug Evaluation Studies, Preclinical,Drug Evaluations, Preclinical,Evaluation Studies, Drug, Preclinical,Evaluation, Preclinical Drug,Evaluations, Preclinical Drug,Medicinal Plants Testing, Preclinical,Preclinical Drug Evaluation,Preclinical Drug Evaluations,Drug Screenings,Screening, Drug,Screenings, Drug
D000595 Amino Acid Sequence The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION. Protein Structure, Primary,Amino Acid Sequences,Sequence, Amino Acid,Sequences, Amino Acid,Primary Protein Structure,Primary Protein Structures,Protein Structures, Primary,Structure, Primary Protein,Structures, Primary Protein
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D017434 Protein Structure, Tertiary The level of protein structure in which combinations of secondary protein structures (ALPHA HELICES; BETA SHEETS; loop regions, and AMINO ACID MOTIFS) pack together to form folded shapes. Disulfide bridges between cysteines in two different parts of the polypeptide chain along with other interactions between the chains play a role in the formation and stabilization of tertiary structure. Tertiary Protein Structure,Protein Structures, Tertiary,Tertiary Protein Structures
D051379 Mice The common name for the genus Mus. Mice, House,Mus,Mus musculus,Mice, Laboratory,Mouse,Mouse, House,Mouse, Laboratory,Mouse, Swiss,Mus domesticus,Mus musculus domesticus,Swiss Mice,House Mice,House Mouse,Laboratory Mice,Laboratory Mouse,Mice, Swiss,Swiss Mouse,domesticus, Mus musculus
D054832 Urocortins Neuropeptides of about 40 amino acids which are structurally similar to CORTICOTROPIN-RELEASING FACTOR. Unlike CRF acting primarily through type 1 CRF RECEPTORS, urocortins signal preferentially through type 2 CRF receptors. Urocortins have wide tissue distribution from fish to mammals, and diverse functions. In mammals, urocortins can suppress food intake, delays gastric emptying, and decreases heat-induced edema. Urocortin,Ucn II,Ucn III,Urocortin 1,Urocortin 2,Urocortin 3,Urocortin I,Urocortin II,Urocortin III

Related Publications

Christian Devigny, and Francisco Perez-Balderas, and Bastiaan Hoogeland, and Serena Cuboni, and Rudolf Wachtel, and Christoph P Mauch, and Katharine J Webb, and Jan M Deussing, and Felix Hausch
September 2007, Current neuropharmacology,
Christian Devigny, and Francisco Perez-Balderas, and Bastiaan Hoogeland, and Serena Cuboni, and Rudolf Wachtel, and Christoph P Mauch, and Katharine J Webb, and Jan M Deussing, and Felix Hausch
August 2013, Nature reviews. Drug discovery,
Christian Devigny, and Francisco Perez-Balderas, and Bastiaan Hoogeland, and Serena Cuboni, and Rudolf Wachtel, and Christoph P Mauch, and Katharine J Webb, and Jan M Deussing, and Felix Hausch
January 2017, Chemical reviews,
Christian Devigny, and Francisco Perez-Balderas, and Bastiaan Hoogeland, and Serena Cuboni, and Rudolf Wachtel, and Christoph P Mauch, and Katharine J Webb, and Jan M Deussing, and Felix Hausch
January 1998, Receptors & channels,
Christian Devigny, and Francisco Perez-Balderas, and Bastiaan Hoogeland, and Serena Cuboni, and Rudolf Wachtel, and Christoph P Mauch, and Katharine J Webb, and Jan M Deussing, and Felix Hausch
December 2013, Angewandte Chemie (International ed. in English),
Christian Devigny, and Francisco Perez-Balderas, and Bastiaan Hoogeland, and Serena Cuboni, and Rudolf Wachtel, and Christoph P Mauch, and Katharine J Webb, and Jan M Deussing, and Felix Hausch
August 2018, Current opinion in structural biology,
Christian Devigny, and Francisco Perez-Balderas, and Bastiaan Hoogeland, and Serena Cuboni, and Rudolf Wachtel, and Christoph P Mauch, and Katharine J Webb, and Jan M Deussing, and Felix Hausch
January 2020, Annual review of pharmacology and toxicology,
Christian Devigny, and Francisco Perez-Balderas, and Bastiaan Hoogeland, and Serena Cuboni, and Rudolf Wachtel, and Christoph P Mauch, and Katharine J Webb, and Jan M Deussing, and Felix Hausch
January 2001, Genome biology,
Christian Devigny, and Francisco Perez-Balderas, and Bastiaan Hoogeland, and Serena Cuboni, and Rudolf Wachtel, and Christoph P Mauch, and Katharine J Webb, and Jan M Deussing, and Felix Hausch
May 2012, British journal of pharmacology,
Christian Devigny, and Francisco Perez-Balderas, and Bastiaan Hoogeland, and Serena Cuboni, and Rudolf Wachtel, and Christoph P Mauch, and Katharine J Webb, and Jan M Deussing, and Felix Hausch
January 2004, Acta biochimica Polonica,
Copied contents to your clipboard!